CD3 stimulants(T cell surface glycoprotein CD3 stimulants), GPRC5D inhibitors(G-protein coupled receptor family C group 5member D inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Refractory Multiple MyelomaRelapse multiple myelomaMultiple Myeloma+ [6]

Inactive Indication-

Originator Organization

Janssen Pharmaceuticals, Inc.

Active Organization

Janssen Research & Development LLCJanssen-Cilag Pty Ltd.

Johnson & Johnson (China) Investment Ltd.

+ [9]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (09 Aug 2023),

Multiple Myeloma

RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Conditional marketing approval (China), Orphan Drug (Japan), Orphan Drug (South Korea), Conditional marketing approval (European Union), Breakthrough Therapy (China), Priority Review (China)

Structure/Sequence

Sequence Code 10086313H

Source: *****

Sequence Code 10086327L

Source: *****

Sequence Code 453116282H

Source: *****

Sequence Code 525754800L

Source: *****

Clinical Trials associated with Talquetamab

NCT07474961

/ Not yet recruitingPhase 4IIT

A Multicentre, Adaptive, Randomised, Multidomain, Platform Trial for Dose Optimization in the Treatment of Adult Patients With Haematological Diseases (BLOOD-dose): Core Protocol

BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases.
The BLOOD-dose core protocol outlines the overall clinical trial design that applies to all included interventions, while domain-specific appendices (DSA) detail the unique characteristics of each domain and specify domain-specific interventions.
New domains will be incorporated over time to address distinct dose-optimization research questions across different haematological conditions and interventions.

Start Date01 Mar 2027

Sponsor / Collaborator

Rigshospitalet

NCT07720843

/ Not yet recruitingPhase 1IIT

TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)

This is a Phase 1, open-label dose escalation study evaluating the safety and clinical efficacy of Talquetamab in combination with Belantamab mafodotin for a time-limited interval followed by Belantamab mafodotin and Pomalidomide maintenance.
The study will enroll subjects with Multiple Myeloma that have previously been treated with at least one prior line of therapy and have been treated with IMiDs, proteasome inhibitors, and anti-CD38 therapies either in combination or as single agent and are relapsed or are refractory to, or intolerant of, established therapies with clinical benefit in Multiple Myeloma.
Talquetamab will be administered with step up dosing on day 1, 3, 5 with or without day 7 pending target dose (TD1) of Talquetamab (Tal) in dose level. Two weeks after TD1, patients will enroll on C1D1 of Tal (TD2) with Belantamab (Bela). Tal will subsequently be dosed every two weeks. Bela will be administered every 8 weeks on D1 of odd numbered cycles or until resolution of any ocular toxicities to grade 1 or better. After 6 cycles of induction, patients may transition to Bela/Pom maintenance.

Start Date01 Sep 2026

Sponsor / Collaborator

Montefiore Medical Center

[+1]

NCT07657312

/ RecruitingPhase 2IIT

Phase 2 Study of Cytokine Release Syndrome Prophylaxis With Infliximab for Teclistamab/Talquetamab Therapy in Patients With Relapsed/Refractory Myeloma

This phase II trial tests how well giving infliximab works for the prevention of cytokine release syndrome (CRS) during treatment with teclistamab or talquetamab in patients with multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). CRS and neurologic toxicity (damage to the nervous system which includes the brain, spinal cord, and nerves) are potential risks of treatment with talquetamab and teclistamab. CRS involves a release of a large amount of proteins into the bloodstream causing inflammation. This may cause changes in blood pressure and heartbeat, flu-like symptoms (nausea, fever, and chills), and/or affect the lung/liver/kidney function. It may also cause certain brain-related symptoms, such as dizziness, weakness, confusion, difficulty speaking, and/or decreased brain function (possible paralysis and/or coma). Infliximab is a drug that prevents the tumor necrosis factor-alpha (TNF-α) from working. TNF-α is a cytokine, or chemical messenger, that helps your immune system produce inflammation. Giving infliximab may work well for the prevention of cytokine release syndrome during treatment with teclistamab or talquetamab in patients with relapsed or refractory multiple myeloma.

Start Date01 Aug 2026

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

[+2]

100 Clinical Results associated with Talquetamab

100 Translational Medicine associated with Talquetamab

100 Patents (Medical) associated with Talquetamab

139

Literatures (Medical) associated with Talquetamab

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care

Article

Author: Mu, Fan ; Patel, Neel ; Yang, Chelsey ; Jiao, Tianze ; Liu, Yi-Hsuan ; Grajales-Cruz, Ariel F. ; Lee, Hans C. ; Zhang, Xinke ; Wang, Jiamin ; Goble, Joseph

AIMS:

To evaluate costs per responder for patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma (RRMM) receiving talquetamab (Tal) on weekly (QW) and biweekly (Q2W) dosing schedules, compared with usual care from a United States commercial payer's perspective.

METHODS:

A cost per responder model was developed over a 6-month time horizon, incorporating pre-progression and post-progression costs. For Tal QW and Tal Q2W, pre-progression costs included costs of drug acquisition, inpatient step-up doses (hospitalization, pre-medication, and tocilizumab), outpatient visits, and monitoring. Pre-progression costs for usual care were estimated based on a weighted average of the 10 most used regimens in a real-world LocoMMotion/MoMMent study, including costs of acquisition, administration, co-medication, and monitoring. Post-progression costs included subsequent treatment for a subset of patients and terminal care costs prior to death. All costs were reported in 2025 United States Dollars. Clinical data of overall response rate (ORR), progression-free survival, and overall survival were obtained from an indirect treatment comparison using MonumenTAL-1 (September 2024 data cut) and LocoMMotion/MoMMent (October 2022 and August 2023 data cuts) as data sources. Deterministic sensitivity analyses and scenario analyses were conducted to assess the robustness of model results.

RESULTS:

Over the 6-month period, the total cost of care was $179,556 for usual care, $295,993 for Tal QW, and $315,135 for Tal Q2W. Despite higher costs, Tal demonstrated superior ORR, resulting in lower cost per responder: $575,962 for usual care, $405,470 for Tal QW, and $443,165 for Tal Q2W, representing a 23-30% reduction in cost per responder with Tal. Sensitivity and scenario analyses showed consistent findings.

CONCLUSION:

Although Tal QW and Q2W are associated with higher total per-patient costs compared with usual care, they offer improved clinical effectiveness, resulting in lower cost per responder. These findings suggest greater economic value for Tal in the treatment of TCE RRMM.

01 Jun 2026·JCO Oncology Practice

Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses

Article

Author: Giralt, Sergio ; Mailankody, Sham ; Shah, Gunjan L. ; Modelevsky, Lisa ; Mitchell, Aaron ; Landau, Heather J. ; Tan, Carlyn R. ; Patel, Dhwani ; Korde, Neha ; Firestone, Ross S. ; Hashmi, Hamza ; Hultcrantz, Malin L. ; Chan, Amelia ; Hamadeh, Issam S. ; Scordo, Michael ; Rajeeve, Sridevi ; Wang, Alice X. ; Shekarkhand, Tala ; Hassoun, Hani ; Lesokhin, Alexander M. ; Shah, Urvi A. ; Usmani, Saad Z. ; Maclachlan, Kylee

PURPOSE:

Talquetamab is a G protein–coupled receptor class C group 5 member D T-cell–engaging antibody, approved for relapsed/refractory multiple myeloma (RRMM). In the MonumenTAL-1 clinical trial, cytokine release syndrome (CRS) occurred at a frequency of 77%; however, there was no assessment of CRS rates by step-up dose. The primary objective of this study was to characterize CRS rates after each talquetamab step-up dose in a real-world setting.

METHODS:

Patients with RRMM who completed the talquetamab once a week or once every 2 weeks step-up dosing schedule between September 2023 and November 2024 were identified via the institutional database. CRS rate after each talquetamab step-up dose was compared using the chi-square/Fisher’s exact test. The Kruskal-Wallis test was used to compare difference in median time to the CRS onset. Multivariate logistic regression analysis was performed to identify predictors of CRS.

RESULTS:

Fifty patients completed the talquetamab step-up dosing phase during the study period; CRS occurred at a rate of 80%. Pairwise comparisons revealed significant differences in CRS rates between the fourth dose (4%) and each of step-up dose 1 (28%, P = .014) and 2 (34%, P = .003). The only CRS event with fourth dose was grade 1. The median time to onset of first CRS did not differ significantly between step-up doses ( P = .441). Previous exposure to T-cell–redirecting therapy had no impact on CRS incidence (odds ratio: 0.20 [95% CI, 0.03 to 1.10]).

CONCLUSION:

Our findings suggested that the fourth talquetamab dose could be administered in outpatient settings given its high tolerability. The reduced hospitalization period for talquetamab step-up dosing could reduce health care expenses.

01 Jun 2026·EUROPEAN JOURNAL OF HAEMATOLOGY

Salvage Therapy in Multiple Myeloma With Prior T‐Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide

Article

Author: Phull, Pooja ; Siegel, David ; Biran, Noa ; Parmar, Harsh ; Di Palma‐Grisi, James ; Vesole, David

ABSTRACT:

Multiple myeloma (MM) is a hematologic malignancy manifested by proliferation of clonal plasma cells leading to end‐organ damage. Despite significant advancements in therapeutics, it remains incurable. Cellular therapies such as chimeric antigen receptor (CAR‐T) therapy and T‐cell engager (TCE) therapies have delivered high overall response rates, but almost all patients relapse and subsequent options are limited particularly in view of the increasing prevalence of prior exposure to anti‐BCMA agents and immunomodulator (IMiD) therapies. Our retrospective review of 12 patients between January 2024 and December 2025 who received a combination of talquetamab, elranatamab, or teclistamab with pomalidomide found that 11 of 12 had an overall response, of whom 6 had very good partial response or better at median follow‐up of 9.9 months. All 12 patients were prior exposed to pomalidomide, of whom 10 had been exposed to prior CAR‐T with a median of 7 prior lines of therapy. Safety profiles were favorable: 6 patients experienced Grade 1 CRS, 7 experienced Grade III neutropenia, and 7 of 8 patients receiving talquetamab experienced on‐target, off‐tumor side effects like dysgeusia and skin dryness.

166

News (Medical) associated with Talquetamab

31 Jul 2026

·healthcare-digital.com

Johnson & Johnson and Firefly: Targeting KRAS-Driven Cancers

Johnson & Johnson has built one of the industry's most diversified oncology portfolios. Credit: National Cancer Institute / Unsplash Johnson & Johnson is hoping it can improve treatment outcomes for one of oncology’s toughest challenges after confirming the acquisition of Firefly Bio KRAS mutations occur in roughly one in five human cancers , making them among the most common oncogenic drivers. The mutations multiply rapidly, making them challenging to treat, and are particularly common in pancreatic cancer sufferers, where the vast majority of tumours contain a KRAS mutation. After completing its acquisition of Firefly Bio, a preclinical biotechnology company developing targeted protein degradation cancer therapies, Johnson & Johnson is hoping Firefly's degrader antibody conjugate (DAC) technology can improve treatment outcomes for one of oncology's most difficult molecular targets. Using its proprietary FireLink DAC platform, Firefly aims to selectively deliver protein degraders to cancer cells, initially targeting KRAS-driven solid tumours. A new approach to KRAS treatment John Reed, Executive Vice President of Pharmaceuticals and R&D at Johnson & Johnson Innovative Medicine, believes the acquisition will deliver more meaningful and lasting treatment options for patients battling KRAS-driven cancer. On LinkedIn following the acquisition’s confirmation, he writes, “Despite recent advances, improvements in treatments for KRAS-driven cancers are still needed, with the aim of reducing toxicities and prolonging the durability of responses. John Reed, Executive Vice President of Pharmaceuticals and R&D at Johnson & Johnson Innovative Medicine. Credit: Johnson & Johnson By delivering a highly selective KRAS protein degrader directly into tumour cells, the DAC platform is designed to target degrader molecules where they are needed, while preserving healthy tissues – potentially overcoming key limitations associated with existing untargeted approaches.” Why are KRAS-driven cancers so difficult to treat? For decades, KRAS was considered "undruggable" because: The protein has a very smooth surface with few places for drugs to bind. It binds its natural fuel molecule (GTP) extremely tightly. It naturally cycles rapidly between active and inactive states, making it difficult for drugs to bind effectively. Until recently, treatment options have largely been limited to chemotherapy, immunotherapy and therapies targeting pathways downstream of KRAS. A diverse oncology portfolio Johnson & Johnson has built one of the industry's most diversified oncology portfolios, spanning conventional biologics, cell therapies and next-generation targeted treatment platforms. It includes established multiple myeloma treatments Darzalex and Carvykti, alongside newer medicines such as Rybrevant, Talvey and Tecvayli. Firefly marks the company's latest investment in next-generation oncology technologies. Prior to the Firefly acquisition, Johnson & Johnson’s most recent oncology deal was the US$3.05bn purchase of clinical-stage biotech firm Halda Therapeutics in December 2025, which expanded its presence in solid tumours through Halda's RIPTAC platform. Jennifer Taubert, Executive Vice President and Worldwide Chairman of Johnson & Johnson Innovative Medicine. Credit: Johnson & Johnson. Speaking at the time of the Halda Therapeutics acquisition, Jennifer Taubert, Executive Vice President and Worldwide Chairman at Johnson & Johnson Innovative Medicine, says, “This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines. “We are excited to formally welcome the talented Halda team to Johnson & Johnson and look forward to working together to achieve our shared goal of eliminating cancer.” Acquiring biotech firms before clinical maturity Firefly Bio is the latest example of a growing trend in pharmaceutical M&A, with major drugmakers increasingly acquiring early-stage platform companies to secure access to emerging modalities such as protein degradation, antibody-drug conjugates and radiopharmaceuticals that could underpin the next generation of precision oncology treatments. Given the high costs associated with clinical-stage, low-risk oncology assets, such as GSK’s US$10.6bn acquisition of Nuvalent , purchasing a comparatively inexpensive early-stage platform capable of generating multiple future therapies represents an attractive long-term investment for healthcare’s biggest players. Company portals Johnson & Johnson Executives Jennifer Taubert Executive Vice President, Worldwide Chairman and Innovative Medicine John Reed Executive Vice President, Innovative Medicine, Research & Development

AcquisitionImmunotherapy

27 Jul 2026

·www.fiercebiotech.com

Legend Biotech CEO abruptly steps down without permanent replacement

In a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named. After Huang handed in his notice, Legend’s board appointed Alan Bash as the company’s interim CEO on July 23, an SEC filing (PDF) shows. A “comprehensive search process to identify a permanent successor” is underway, the company said in a July 27 press release. Bash joined Legend as president of Carvykti in 2024, four years after Huang’s elevation from CFO to CEO when the company’s founder Fangliang Zhang, Ph.D., was under investigation in China over customs issues. Zhang returned to his post as Legend’s chairman in 2022 as authorities closed the probe without any charges. In his role, Bash has been managing Legend’s commercial operations, specifically, Carvykti, the Johnson & Johnson-partnered multiple myeloma CAR-T therapy, which is the bread and butter of Legend’s business. Huang’s resignation “was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices or the Company’s financial statements or internal controls over financial reporting,” Legend said in a July 27 SEC filing. Huang will remain as an advisor through August to support a smooth transition. That seemingly amicable exit stands in contrast to Legend’s past leadership drama, notably its messy split with scientific co-founder and former chief scientific officer, Frank Fan, M.D., Ph.D., in 2022, which triggered lawsuits that eventually didn’t go Legend’s way. “On behalf of the Board, I want to thank Ying for his leadership, dedication and many contributions to Legend Biotech during the past seven years,” Zhang said in a July 27 statement. “During his tenure, Legend Biotech advanced from a pioneering cell therapy company into a global leader with a strong commercial foundation, a differentiated innovation platform, and a clear commitment to patients. We are grateful for Ying’s continued support through the transition and wish him well in his next chapter.” As for Bash, his “immediate focus will be on ensuring continuity across the business, maintaining strong execution, and supporting our teams as we continue advancing our commercial, clinical, and operational priorities,” according to a statement. In the past two years or so, Legend has come under pressure from potential competition to Carvykti, as well as geopolitical risks given its ties to China. Legend’s stock price hit its lowest in years in February amid ongoing concerns regarding rival treatments such as Gilead Sciences’ CAR-T candidate anito-cel and J&J’s bispecific antibody regimens. Legend’s shares enjoyed a rally in early June after the company reported encouraging early-phase data for LB2501, a CD19/CD20 dual-targeting in vivo CAR-T therapy. Data revealed at the 2026 American Society of Clinical Oncology included a 100% objective response rate at the highest-dose cohort of six patients with pretreated B-cell non-Hodgkin lymphoma, an 83.3% complete response rate, with a relatively clean safety profile without any serious adverse events or neurotoxicity. However, the company’s stock price has since fallen back to pre-ASCO levels as concerns over Carvykti’s market position and the lack of mid- to late-stage pipeline assets took hold again. On July 15, while partner J&J reported another record quarter of Carvykti sales that roughly met analysts’ expectations, Legend’s shares dropped 10% . On J&J’s earnings call that day, Jennifer Taubert, worldwide chair of innovative medicine, described the company’s off-the-shelf combination of Tecvayli and Darzalex as holding “the potential for cure” in previously treated myeloma. Then on July 23, the day that Bash was named interim CEO of Legend, J&J reported jaw-dropping efficacy from its dual-bispecific combination of Tecvayli and Talvey. Compared with standard of care, the two T-cell engagers improved progression-free survival by 89% and overall survival by 62% in earlier-line myeloma.

Executive ChangeClinical ResultASCO

24 Jul 2026

·www.biopharmadive.com

Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma

Today, a brief rundown of news involving Novo Nordisk and Johnson & Johnson, as well as updates from Revolution Medicines, AstraZeneca and Formation Bio that you may have missed.Novo Nordisk on Friday escalated its legal fight with Eli Lilly, asking a New Jersey District Court to block the Indanapolis companys allegedly misleading obesity drug ads. Novo sued Lilly on Tuesday, arguing Lilly is using deceptive ads to claim its GLP-1 products are broadly superior to Novos medicines and that Lilly had ignored a cease-and-desist order. Lilly denied the allegations and said its campaign is truthful. Through a court motion filed Friday, Novo is now seeking a preliminary injunction that would immediately halt those ads. Every day Lillys campaigns run, they divert patients to Zepbound and Mounjaro, entrench false impressions of Wegovys and Ozempics inferiority, and erode goodwill Novo Nordisk has spent decades building, Novos lawyers wrote in court papers. Money damages cannot undo that harm. Ben FidlerA drug combination from Johnson & Johnson helped reduce the risk of disease progression or death by 89% compared to standard treatments in earlier-line multiple myeloma, the company said Monday. The tandem of J&Js bispecific drugs Talvey and Tecvayli alongside pomalidomide also reduced the risk of death alone by 62% in the trial, which evaluated the regimen in patients whod received one to four previous lines of treatment. The results were the best ever reported for bispecific treatments in relapsed-refractory multiple myeloma and help reinforce J&Js dominance across all lines of therapy in the disease, wrote RBC Capital Markets analyst Trung Huynh. J&J will share the results with regulators and present them at a future medical meeting. Ben FidlerRevolution Medicines said Wednesday that the Food and Drug Administration has accepted the approval application for its pancreatic tumor medicine daraxonrasib. The drug has been described by medical experts in recent months as unprecedented and landscape-changing for nearly doubling survival, compared to chemotherapy, in a historically tough-to-treat cancer. U.S. regulators previously granted Revolution a national priority voucher to speed the approval process, giving Revolution the chance at an earlier-than-usual start to generating sales. If approved, some analysts believe it could generate at its peak as much as $10 billion annually. Gwendolyn WuEuropean regulators approved Thursday a drug combination from AstraZeneca that will be used in first-line advanced ER-positive breast cancer. The pairing of camizestrant, or Etcamah, and a CDK 4/6 inhibitor proved more effective than the standard of care, a combination of aromatase and CDK 4/6 inhibitors, in a Phase 3 study, the company said. Data show that AstraZenecas drug combination reduced the risk of disease progression or death by 56%. The FDA announced in May it was delaying a decision on Etcamah, which is part of a new wave of oral selective estrogen receptor degrader drugs. Gwendolyn WuAI drug discovery firm Formation Bio tapped serial biotech entrepreneur Michael Ehlers to step in as its next chief scientific officer, the company said Wednesday. Ehlers, whose prior stops include MPM BioImpact and Apple Tree Partners, founded startups such as Ascidian Therapeutics, Replicate Bioscience, Aulos Bioscience and Intergalactic Therapeutics. In his new role, Ehlers will oversee the creation and advancement of our growing portfolio of innovative medicines, and guide the scientific direction of Formation Bios AI platform, he said in a LinkedIn post. The biotech last raised $372 million in 2024. Gwendolyn Wu '

Phase 3Clinical ResultExecutive ChangeDrug Approval

100 Deals associated with Talquetamab

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Refractory Multiple Myeloma	Japan	Janssen Pharmaceutical KK	24 Jun 2025
Relapse multiple myeloma	Japan	Janssen Pharmaceutical KK	24 Jun 2025
Multiple Myeloma	United States	Janssen Biotech, Inc.	09 Aug 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Residual Neoplasm	Phase 3	-	Johnson & Johnson	01 Sep 2026
Recurrent Multiple Myeloma	Phase 2	United States	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Aug 2026
Recurrent Multiple Myeloma	Phase 2	United States	Janssen Research & Development LLC	01 Aug 2026
Peripheral Stem Cell Transplantation	Phase 2	United States	Janssen Scientific Affairs LLC	05 Jun 2025
Smoldering Multiple Myeloma	Phase 2	United States	Janssen Scientific Affairs LLC	04 Dec 2023
Extramedullary Disease in Multiple Myeloma	Phase 2	Spain	Janssen Pharmaceutica NV	21 Sep 2023
Hematologic Neoplasms	Phase 1	United States	Janssen Research & Development LLC	16 Dec 2017
Hematologic Neoplasms	Phase 1	Belgium	Janssen Research & Development LLC	16 Dec 2017
Hematologic Neoplasms	Phase 1	Netherlands	Janssen Research & Development LLC	16 Dec 2017
Hematologic Neoplasms	Phase 1	Spain	Janssen Research & Development LLC	16 Dec 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05455320 (MonumenTAL-3, Pubmed \| N Engl J Med)	Phase 3	-	864	Talquetamab-Daratumumab-Pomalidomide	jrtbjhsmrh(bmmwcmazyg) = fcoohewiug cgljujqnap (tvxfwhrqmi ) View more	Positive	13 Jun 2026
				Talquetamab-Daratumumab	jrtbjhsmrh(bmmwcmazyg) = hukrnjdlwy cgljujqnap (tvxfwhrqmi ) View more
ASCO2026	Not Applicable	Multiple Myeloma	542	Talquetamab+IVIG	iuyshvakjc(wknikimljt) = swxbfgwozq bcbepvjkrn (mryzloeitp ) View more	Positive	29 May 2026
				Talquetamab	iuyshvakjc(wknikimljt) = tmhpyijjvt bcbepvjkrn (mryzloeitp ) View more
ASCO2026	Not Applicable	Relapse multiple myeloma	402	Talquetamab	ggcfkpqdlf(ullevrfxhs) = xlpkxipuhv uamrxkzqoz (irwhvogygw ) View more	Positive	29 May 2026
				Teclistamab	ggcfkpqdlf(ullevrfxhs) = iqunbimacm uamrxkzqoz (irwhvogygw ) View more
ASCO2026	Not Applicable	Relapse multiple myeloma	590	Talquetamab	uuxowmcheh(cxonryqfcx) = ER visits (HR = 0.716), anemia (HR = 0.915), sepsis (HR = 0.803), and pneumonia (HR = 0.641) were numerically lower in the talquetamab group but were not statistically significant (p > 0.05). Neutropenia (HR = 1.082), thrombocytopenia (HR = 1.301), and CRS (HR = 1.617) did not differ significantly (p > 0.05). Hospitalization, MM relapse, and neurotoxicity were not analyzable due to low events. flmdmxxxti (nwyvlvcfvl ) View more	Positive	29 May 2026
				Sequential BDT
ASCO2026	Not Applicable	Refractory Multiple Myeloma	1,941	Talquetamab	ilfxceecoh(kxplfdifju) = TQ group had higher risk for developing CRS (RR 1.91 (1.34, 2.72), p<0.0001) zxjhawcdwl (lvardyzmyu ) View more	Positive	29 May 2026
				Teclistamab
ASCO2026	Not Applicable	Refractory Multiple Myeloma	78	Talquetamab	olzcwjlisx(kvufenrbsn) = nadpixlsvk grbzxsewqw (apuwoxcygz, 0.27 - 0.4) View more	Positive	29 May 2026
				Elranatamab	olzcwjlisx(kvufenrbsn) = rdamhplqse grbzxsewqw (apuwoxcygz, 0.19 - 0.49) View more
ASCO2026	Not Applicable	Multiple Myeloma BCMA	7,280	Ide-cel	llrdlbvfki(clyeplgece) = achypuvcym vsbdajgprp (fmkjudeawg ) View more	Negative	29 May 2026
				Cilta-cel	llrdlbvfki(clyeplgece) = uxuwovctgb vsbdajgprp (fmkjudeawg ) View more
NCT04586426 (RedirecTT-1, ASCO2026)	Phase 1/2	Relapse multiple myeloma	114	Talquetamab 0.8 mg/kg + Teclistamab 1.5 mg/kg Q2W	kijpdkmqpg(lsfrfskffa) = wenkxjjkrh xadwmjncfz (tdlbfkqdsq ) View more	Positive	29 May 2026
				Talquetamab 0.8 mg/kg + Teclistamab 3.0 mg/kg	kijpdkmqpg(lsfrfskffa) = rwslwyzlxm xadwmjncfz (tdlbfkqdsq ) View more
NCT05972135 (ASCO2026)	Phase 2	Relapse multiple myeloma	50	TocilizumabTeclistamab + TocilizumabTeclistamab	wrnplfkydh(rgmuvljigc) = buiqphsuny klxqobekfh (uhczhhcfxe ) View more	Positive	29 May 2026
				TocilizumabTalquetamab + TocilizumabTalquetamab	wrnplfkydh(rgmuvljigc) = vdbqycsemf klxqobekfh (uhczhhcfxe ) View more
NCT06500884 (TALISMAN, EHA2026)	Phase 2	Relapse multiple myeloma	30	Talquetamab with dexamethasone oral rinse prophylaxis (prophy Dex)	oacoqapzsp(yfxextlmlf) = lupcqyralp idqpquevoa (ahirjuiajp ) View more	Positive	12 May 2026
				Talquetamab only (control)	qdisaifbor(ghznmvsefn) = ixcykxuapk xelwlwzqkg (qshovctyru ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis